Epidemiology and Natural History of Childhood-Acquired Chronic Hepatitis C: A Single-Center Long-Term Prospective Study.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
3
6
2022
medline:
27
7
2022
entrez:
2
6
2022
Statut:
ppublish
Résumé
To prospectively describe the epidemiology and long-term outcome of childhood-acquired hepatitis C virus (HCV) infection in a large cohort of children followed at a single center. All children with chronic HCV infection followed at the Liver Unit of our tertiary Hospital in Florence (Italy) from January 1, 1988, to September 30, 2021, were included in the analysis. The final sample consisted of 163 children (median age at enrollment 4 years, interquartile range (IQR): 10; median age at last follow-up 14 years, IQR: 7). The median duration of follow-up was 86 months (IQR: 112). One hundred twenty-five children were vertically infected and 26 acquired the infection horizontally. Twenty-six of the 125 children who were vertically infected (20.8%) underwent spontaneous clearance of HCV RNA at a median age of 4 years (IQR: 2), whereas all the others remained persistently viremic. One patient was diagnosed with cirrhosis; 2 presented clinically detectable extrahepatic manifestations (chronic urticaria). Thirty-two children (19.6%) received antiviral therapy: 8 out of 32 (25%) were treated with pegylated-interferon alfa-2b [sustained virological response (SVR) 24 weeks after the end of treatment in 7/8]; 24 out of 32 (75%) were treated with direct-acting antivirals (SVR 12 weeks after the end of treatment in 23/24). The present study describes the largest cohort of children with chronic HCV infection prospectively evaluated with a long follow-up at a single center. HCV infection in children is often a chronic infection that can be cured with modern antiviral therapy. Early treatment could prevent the development of advanced liver disease.
Identifiants
pubmed: 35653496
doi: 10.1097/MPG.0000000000003481
pii: 00005176-202208000-00004
doi:
Substances chimiques
Antiviral Agents
0
Ribavirin
49717AWG6K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2-e7Informations de copyright
Copyright © 2022 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
The World Health Organisation. WHO Global Hepatitis Report, 2017. Geneva: World Health Organization; 2017.
Schmelzer J, Dugan E, Blach S, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol. 2020;5:374–92.
El–Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:477–87.
European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis c virus infection. Clin Infect Dis. 2005;41:45–51.
Bortolotti F, Verucchi G, Cammà C, et al. Long-term course of chronic hepatitis c in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008;134:1900–7.
Modin L, Arshad A, Wilkes B, et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol. 2019;70:371–8.
Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol. 2014;11:28–35.
Indolfi G, Azzari C, Resti M. Perinatal transmission of hepatitis C virus. J Pediatr. 2013;163:1549–1552.e1.
The World Health Organisation. WHO Guidelines on Hepatitis B and C Testing. Vol. 66. Geneva: World Health Organization; 2017:1–170.
D’Antiga L. Pediatric Hepatology and Liver Transplantation. Cham: Springer International Publishing; 2019.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.
Indolfi G, Mangone G, Bartolini E, et al. Hepatitis C viraemia after apparent spontaneous clearance in a vertically infected child. Lancet. 2016;387:1967–8.
Serranti D, Indolfi G, Caudai C, et al. Hepatitis c genotype 4 virus nonstructural 3 and nonstructural 5a resistance-associated substitutions in a 16-year-old adolescent failing ombitasvir/paritaprevir/ritonavir plus ribavirin. Pediatr Infect Dis J. 2019;38:e72–4.
Indolfi G, Nesi A, Resti M, et al. Intrafamilial transmission of hepatitis C virus. J Med Virol. 2013;85:608–14.
Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults-Massachusetts, 2002-2009. Am J Transplant. 2011;11:1535–8.
Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - kentucky, tennessee, virginia, and west virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015;64:453–8.
Resti M, Jara P, Hierro L, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol. 2003;70:373–7.
Mangone G, Serranti D, Bartolini E, et al. SNPs of the IFNL favour spontaneous clearance of HCV infection in children. Pediatr Res. 2022;91:1516–1521.
Indolfi G, Mangone G, Calvo PL, et al. Interleukin 28B rs12979860 single-nucleotide polymorphism predicts spontaneous clearance of hepatitis C virus in children. J Pediatr Gastroenterol Nutr. 2014;58:666–8.
Indolfi G, Mangone G, Bartolini E, et al. Comparative analysis of rs12979860 SNP of the IFNL3 gene in children with hepatitis C and ethnic matched controls using 1000 Genomes Project data. PLoS One. 2014;9:e85899.
Indolfi G, Bartolini E, Olivito B, et al. Autoimmunity and extrahepatic manifestations in treatment-naïve children with chronic hepatitis C virus infection. Clin Dev Immunol. 2012;2012:785627.
Robinson JL, Doucette K. The natural history of hepatitis C virus infection acquired during childhood. Liver Int. 2012;32:258–70.
García-Monzón C, Jara P, Fernández-Bermejo M, et al. Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients. Hepatology. 1998;28:1696–701.
Indolfi G, Guido M, Azzari C, et al. Histopathology of hepatitis C in children, a systematic review: implications for treatment. Expert Rev Anti Infect Ther. 2015;13:1225–35.
Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: Liver biopsy findings in the Peds-C Trial. Hepatology. 2008;47:836–43.
Jara P, Resti M, Hierro L, et al. Chronic hepatitis c virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis. 2003;36:275–80.
Dezsõfi A, Baumann U, Dhawan A, et al. Liver biopsy in children: position paper of the espghan hepatology committee. J Pediatr Gastroenterol Nutr. 2015;60:408–20.
Indolfi G, Hierro L, Dezsofi A, et al. Treatment of chronic hepatitis c virus infection in children: a position paper by the hepatology committee of european society of paediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr. 2018;66:505–15.
Serranti D, Indolfi G, Nebbia G, et al. Transient hypothyroidism and autoimmune thyroiditis in children with chronic hepatitis c treated with pegylated-interferon-α-2b and ribavirin. Pediatr Infect Dis J. 2018;37:287–91.
Indolfi G, Nebbia G, Cananzi M, et al. Kinetic of virologic response to pegylated interferon and ribavirin in children with chronic hepatitis c predicts the effect of treatment. Pediatr Infect Dis J. 2016;35:1300–3.
Serranti D, Nebbia G, Cananzi M, et al. Efficacy of sofosbuvir/ledipasvir in adolescents with chronic hepatitis c genotypes 1, 3, and 4: a real-world study. J Pediatr Gastroenterol Nutr. 2021;72:95–100.
Serranti D, Dodi I, Nicastro E, et al. Shortened 8-week course of sofosbuvir/ledipasvir therapy in adolescents with chronic hepatitis c infection. J Pediatr Gastroenterol Nutr. 2019;69:595–8.
Indolfi G, Fischler B, Gonzalez-Peralta RP, et al. Comparison of recommendations for treatment of chronic hepatitis c virus infection in children and adolescents: a position paper of the federation of international societies of pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr. 2020;70:711–7.
Indolfi G, Giometto S, Serranti D, et al. Systematic review with meta-analysis: the efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2020;52:1125–33.